MiMedx GroupMDXG +3.01%57 Days Payable is 68.28 as of Mar. 2026, which is 12% below its 10-year median of 77.74. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, MiMedx Group ranks worse than 65.63% on this metric.
The historical rank and industry rank for MiMedx Group's Days Payable or its related term are showing as below:
MDXG'
s Days Payable Range Over the Past 10 Years
Min: 50 Med: 77.74 Max: 116.96
Current: 54.16
During the past 13 years, MiMedx Group's highest Days Payable was 116.96. The lowest was 50.00. And the median was 77.74.
MDXG's Days Payable is ranked worse than 65.63% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs MDXG: 54.16
MiMedx Group's Days Payable
increased
from Mar. 2025 (44.85) to Mar. 2026 (68.28).
It may suggest that MiMedx Groupdelayed paying its suppliers.
MiMedx Group Days Payable Related Terms
MiMedx Group Days Payable Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MiMedx Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Days Payable distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
MiMedx Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a Days Payable of 68.28 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MiMedx Group and its competitors. This is 12% below median its historical median of 77.74. Over the past decade, MiMedx Group's Days Payable has ranged from 50.00 to 116.96. According to the industry distribution chart, MiMedx Group ranks #464 out of 707 companies in the Biotechnology industry, placing it in the top 65.6%.
Is MiMedx Group's Days Payable too high?
MiMedx Group's current Days Payable of 68.28 is 12% below median its 10-year median of 77.74. Over the past 10 years, this metric has ranged from a low of 50.00 to a high of 116.96. The Biotechnology industry median Days Payable is 113.76. MiMedx Group's value of 68.28 is 40% below this industry median. Based on the distribution chart, MiMedx Group ranks #464 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Days Payable compare to ASMB and AGMB?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #464 out of 707 companies for Days Payable. This places MiMedx Group in the lower half of its industry. The industry median Days Payable is 113.76. MiMedx Group's value of 68.28 is 40% below this benchmark. Historically, MiMedx Group's own Days Payable has ranged from 50.00 to 116.96 over the past decade. While the company's 10-year median is 77.74 vs. the industry median of 113.76, MiMedx Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Days Payable of 68.28 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MiMedx Group and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Days Payable is 68.28, which is 12% below median its own 10-year median of 77.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.96, compared to a current price of $3.93 — trading 43.5% below its estimated fair value. The current Days Payable is 68.28, which is 12% below median its 10-year median of 77.74 and 40% below the Biotechnology industry median of 113.76. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Days Payable is 68.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.93 is trading 43.5% below its estimated GF Value™ of $6.96.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Days Payable: 68.28 (12% below median its 10-year median of 77.74)
GF Value™: $6.96 vs. price of $3.93 (43.5% below fair value)
Industry Position: 40% below the Biotechnology median (#464 of 707)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
